Expert Interview
A 2nd look at the recent FDA approvals for Regeneron's Eylea HD (aflibercept), for macular edema following retinal vein occlusion (RVO) and the addition of a monthly dosing option across all approved indications.
Ticker(s): REGN, RHHBYInstitution: UC Davis
- Professor of Ophthalmology at UC Davis.
- Manages ~400 patients with wet-AMD.
- Leads a translational research program studying age-related macular degeneration (AMD) and other retinal diseases. Research focuses include ocular imaging technologies, gene editing and delivery, and animal models of retinal disease.
Roughly how many patients do you manage with wet amd?
Added By: sara_adminHow many are on Eylea? Eylea HD?
Added By: sara_adminHow impactful has the approval of Eylea HD been on the treatment of your patients?
Added By: sara_adminHave you prescribed an Eylea biosimilar? If not why?
Does an Eylea biosimilar from a large company like Amgen make it more appealing?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
